CAV\/VVHD      :Unlikely to be dialysed. Dose as in GFR=10\u201325 mL\/min IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAnagrelide: avoid concomitant use Antibacterials: concentration increased by erythromycin; also concentration of erythromycin reduced \u2013 avoid concomitant use. Antifungals: concentration possibly increased by ketoconazole \u2013 avoid concomitant use. Antivirals: concentration possibly increased by amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir \u2013 avoid concomitant useCalcium-channel blockers: concentration increased by diltiazem \u2013 avoid concomitant useUlcer-healing drugs: concentration possibly increased by cimetidine and lansoprazole \u2013 avoid concomitant use; concentration increased by omeprazole \u2013 avoid concomitant use ADMINISTRATION <\/H3> Reconstition<\/H4>\u2013 Route <\/H4>Oral Rate of Administration <\/H4>\u2013Comments<\/H4>\u2013 OTHER INFORMATION <\/H4>There are two major metabolites, a dehydro-cilostazol and a 4\u2019-trans-hydroxy cilostazol, both of which have similar apparent half-lives. The dehydro metabolite is 4\u20137 times as active a platelet anti-aggregant as the parent compound, and the 4\u2019-trans-hydroxy metabolite is one fifth as activeIn subjects with severe renal impairment, the free fraction of cilostazol was 27% higher and both Cmax and AUC were 29% and 39% lower respectively than in subjects with normal renal function. The Cmax and AUC of the dehydro metabolite were 41% and 47% lower respectively in the severely renally impaired subjects compared to subjects with normal renal function. The Cmax and AUC of 4\u2019-trans-hydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment. The drug should be used with great caution if administered to patients with a creatinine clearance <25 mL\/minContraindicated in patients with heart failureCilostazol is under investigation for its antiplatelet effect after coronary stent implantationDose can also be reduced to 50 mg twice daily if used with drugs which affect its clearance.
\n","protected":false},"excerpt":{"rendered":"
Cilostazol CLINICAL USE Intermittent claudication DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3838","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3838"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3838\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}